htert reduction by imetelstat correlates with clinical activity in mds
Published 2 years ago • 717 plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
2:38
imetelstat on-target activity correlates with clinical benefits in mds: imerge findings
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
1:25
imerge subgroup study: imetelstat in patients with lr-mds previously exposed to esas
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
2:19
imetelstat for transfusion-dependent r/r mds
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
4:28
hematologi mindray error hgb blank voltage ubnormal #hematologimindray #mindraybc5150 #hematology
-
2:25
bispectral index™ byte 2: the bis™ index range
-
30:14
hematology analyzer installation and operation video
-
2:00
imetelstat in heavily-transfused lower-risk r/r mds
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
1:56
promising approaches and clinical trials in mds
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
3:50
imetelstat efficacy is independent of molecular subtypes in r/r lr-mds
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
1:44
an update on imetelstat in r/r myelofibrosis